title: Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
abstract: Patients with a baseline viral load >100,000 copies/mL receiving abacavir (ABC) as part of the nucleoside-backbone component of their first highly active antiretroviral therapy (HAART) regimen have been reported to have a greater failure rate than those receiving tenofovir (TDF). We analyzed short-term outcomes of the use of HAART combinations that included ABC or TDF. The mean 2-8-week change in viral load was calculated using linear regression. In total, 1136 patients started ABC, and 412 started TDF. After adjustment for baseline viral load and other factors, there was no difference in the change in viral load between the patients who started ABC and those who started TDF (0.03 [95% confidence interval, -0.07 to 0.12]) log copies/mL; P = .59). Furthermore, there was no evidence that this effect differed according to baseline viral load (P = .88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART.
authors.affiliation: Research Department of Infection and Population Health, University College Medical School, Royal Free Campus, London, United Kingdom. l.bansi@pcps.ucl.ac.uk
authors.forename: Loveleen
authors.initials: L
authors.lastname: Bansi
authors.forename: Caroline
authors.initials: C
authors.lastname: Sabin
authors.forename: Richard
authors.initials: R
authors.lastname: Gilson
authors.forename: Brian
authors.initials: B
authors.lastname: Gazzard
authors.forename: Clifford
authors.initials: C
authors.lastname: Leen
authors.forename: Jane
authors.initials: J
authors.lastname: Anderson
authors.forename: David
authors.initials: D
authors.lastname: Dunn
authors.forename: Teresa
authors.initials: T
authors.lastname: Hill
authors.forename: Martin
authors.initials: M
authors.lastname: Fisher
authors.forename: Jonathan
authors.initials: J
authors.lastname: Ainsworth
authors.forename: Deenan
authors.initials: D
authors.lastname: Pillay
authors.forename: Margaret
authors.initials: M
authors.lastname: Johnson
authors.forename: John
authors.initials: J
authors.lastname: Walsh
authors.forename: Chloe
authors.initials: C
authors.lastname: Orkin
authors.forename: Philippa
authors.initials: P
authors.lastname: Easterbrook
authors.forename: Mark
authors.initials: M
authors.lastname: Gompels
authors.forename: Andrew
authors.initials: A
authors.lastname: Phillips
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D000068698:Tenofovir; D017211:Treatment Failure; D016896:Treatment Outcome; D019562:Viral Load; D000099227:Abacavir
chemical_list: D000225:Adenine; D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D063065:Organophosphonates; D000068698:Tenofovir; D000099227:Abacavir